Addus HomeCare enters its June 10 earnings window with a quietly improving positioning picture — but a 35% gap between the stock price and the analyst consensus target frames the most interesting tension heading into next month.
The stock added less than 1% on the week to close at $98.49, a modest follow-through to the 6.8% gain recorded over the past month. Year-to-date the shares are still down nearly 9%, leaving the stock well below where it began 2026 even as the recent bounce has gathered momentum.
Short positioning has been a quiet tailwind for the stock. SI % FF peaked near 5.9% in early April — during the broad market selloff — and has since unwound steadily. By May 12 it had retreated to 5.0% of free float, a 6.4% week-on-week decline and roughly 15% below its April high. That unwind has come alongside soft borrow conditions: cost to borrow runs below 0.5% and availability remains comfortable, with the lending market far from any squeeze dynamic. The ORTEX short score has ticked down daily all week, falling from 42.0 on May 6 to 40.5 by Tuesday — a consistent signal that the pressure from short sellers is easing rather than building. Options positioning supports that tone. The put/call ratio at 0.27 is slightly below its 20-day average of 0.30, with a z-score of just -0.4. Investors are not rushing to hedge.
The analyst picture is where the tension is sharpest. The mean price target of $133.46 implies roughly 35% upside from current levels — one of the highest return-potential readings visible on the screen. Yet the direction of travel has been downward. Citizens trimmed its target to $142 from $150 on May 6 while keeping a Market Outperform rating, and Barclays — maintaining its lone Underweight — cut its target to $102 in late March, sitting just 4% above the current price. The bull case centres on consistent EBITDA beats, acquisitive growth, and the structural tailwind from home-based care demand. The bear case flags Medicaid funding risk, census softness in personal care, and the possibility that Indiana acquisitions deliver less than expected. Valuation has re-rated modestly higher: the trailing P/E of 13.7x has risen about 1.8% over 30 days, while EV/EBITDA of 9.5x is close to flat. The analyst recommendation divergence factor scores in the 97th percentile — reflecting how wide the gap between the most bullish and most bearish targets currently is.
Institutional ownership tells a stable story. BlackRock leads with 15.4% of shares, with Capital Research and Vanguard rounding out the top three at roughly 8% and 7% respectively. Most holders made marginal changes in the most recent reporting period. Westwood Management stands out — its latest filing showed a full new position of 375,000 shares. That is a meaningful entry from a value-oriented manager, and it aligns with the stock's relatively undemanding multiples compared to peers. Recent insider activity is routine in scale: the 90-day net insider flow is technically positive at roughly 27,000 shares, but the detailed record shows a cluster of small tax-related sales across the C-suite in late February, which are typical of vesting-related disposals rather than directional conviction.
The most recent earnings reaction — a 3.5% decline on May 5 after Q1 results, extending to a 1.6% five-day loss — underlines that the stock has been prone to sell-the-news moves. The prior result in late April triggered a 3.3% gain, so reactions have been inconsistent. Close peers had a better week than ADUS: PNTG gained over 12% and NHC added more than 13%, while AHCO slid 4.3% — a mixed read on sector sentiment rather than a clean directional signal.
With the next earnings call confirmed for June 10, the question for the six weeks ahead is whether the stock's 35% discount to consensus targets reflects a genuine re-rating opportunity or a Street that has been slow to revise down.
See the live data behind this article on ORTEX.
Open ADUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
